Min_max
2021-09-22
good efficiency against the delta variant is a price booster
Dynavax surged over 15% in early trading
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":863001417,"tweetId":"863001417","gmtCreate":1632326167139,"gmtModify":1632801183189,"author":{"id":3585869414507662,"idStr":"3585869414507662","authorId":3585869414507662,"authorIdStr":"3585869414507662","name":"Min_max","avatar":"https://static.tigerbbs.com/a19718c12eabe8d2a0c3e3a797bd178f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":22,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>good efficiency against the delta variant is a price booster</p></body></html>","htmlText":"<html><head></head><body><p>good efficiency against the delta variant is a price booster</p></body></html>","text":"good efficiency against the delta variant is a price booster","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/863001417","repostId":1119012338,"repostType":4,"repost":{"id":"1119012338","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632318193,"share":"https://www.laohu8.com/m/news/1119012338?lang=&edition=full","pubTime":"2021-09-22 21:43","market":"us","language":"en","title":"Dynavax surged over 15% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1119012338","media":"Tiger Newspress","summary":"(Sept 22) Dynavax surged over 15% in early trading. Dynavax partner Clover's COVID-19 vaccine shows ","content":"<p>(Sept 22) Dynavax surged over 15% in early trading. Dynavax partner Clover's COVID-19 vaccine shows 79% efficacy against Delta variant.</p>\n<p><img src=\"https://static.tigerbbs.com/0ee83db70a926108533f3d4f20d96d0a\" tg-width=\"969\" tg-height=\"554\" referrerpolicy=\"no-referrer\"></p>\n<p>Clover Biopharmaceuticalsannounces that its adjuvanted protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) achieved the primary efficacy endpoint and secondary efficacy endpoints in Phase 2/3 SPECTRA trial.</p>\n<p>Trial enrolled over 30,000 adult & elderly participants.</p>\n<p>Vaccine efficacy was successfully demonstrated where 100% of SARS-CoV-2 strains observed in the efficacy analysis were variants.</p>\n<p>79% overall efficacy observed against COVID-19 of any severity caused by globally dominant Delta variant. Efficacy was 92% against Gamma variant and 59% against Mu variant.</p>\n<p>Overall efficacy was 67% against COVID-19 of any severity caused by any strain in the study, successfully meeting the primary endpoint of the trial.</p>\n<p>Vaccination reduced the risk of symptomatic COVID-19 reinfection caused by any strain by 64.2%.</p>\n<p>SCB-2019 demonstrated a favorable safety profile with no significant difference in systemic adverse events compared to placebo.</p>\n<p>The vaccine was created by combining SCB-2019 with Dynavax's(NASDAQ:DVAX)CpG 1018 advanced adjuvant and aluminum hydroxide (alum).</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dynavax surged over 15% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDynavax surged over 15% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-22 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Sept 22) Dynavax surged over 15% in early trading. Dynavax partner Clover's COVID-19 vaccine shows 79% efficacy against Delta variant.</p>\n<p><img src=\"https://static.tigerbbs.com/0ee83db70a926108533f3d4f20d96d0a\" tg-width=\"969\" tg-height=\"554\" referrerpolicy=\"no-referrer\"></p>\n<p>Clover Biopharmaceuticalsannounces that its adjuvanted protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) achieved the primary efficacy endpoint and secondary efficacy endpoints in Phase 2/3 SPECTRA trial.</p>\n<p>Trial enrolled over 30,000 adult & elderly participants.</p>\n<p>Vaccine efficacy was successfully demonstrated where 100% of SARS-CoV-2 strains observed in the efficacy analysis were variants.</p>\n<p>79% overall efficacy observed against COVID-19 of any severity caused by globally dominant Delta variant. Efficacy was 92% against Gamma variant and 59% against Mu variant.</p>\n<p>Overall efficacy was 67% against COVID-19 of any severity caused by any strain in the study, successfully meeting the primary endpoint of the trial.</p>\n<p>Vaccination reduced the risk of symptomatic COVID-19 reinfection caused by any strain by 64.2%.</p>\n<p>SCB-2019 demonstrated a favorable safety profile with no significant difference in systemic adverse events compared to placebo.</p>\n<p>The vaccine was created by combining SCB-2019 with Dynavax's(NASDAQ:DVAX)CpG 1018 advanced adjuvant and aluminum hydroxide (alum).</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119012338","content_text":"(Sept 22) Dynavax surged over 15% in early trading. Dynavax partner Clover's COVID-19 vaccine shows 79% efficacy against Delta variant.\n\nClover Biopharmaceuticalsannounces that its adjuvanted protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) achieved the primary efficacy endpoint and secondary efficacy endpoints in Phase 2/3 SPECTRA trial.\nTrial enrolled over 30,000 adult & elderly participants.\nVaccine efficacy was successfully demonstrated where 100% of SARS-CoV-2 strains observed in the efficacy analysis were variants.\n79% overall efficacy observed against COVID-19 of any severity caused by globally dominant Delta variant. Efficacy was 92% against Gamma variant and 59% against Mu variant.\nOverall efficacy was 67% against COVID-19 of any severity caused by any strain in the study, successfully meeting the primary endpoint of the trial.\nVaccination reduced the risk of symptomatic COVID-19 reinfection caused by any strain by 64.2%.\nSCB-2019 demonstrated a favorable safety profile with no significant difference in systemic adverse events compared to placebo.\nThe vaccine was created by combining SCB-2019 with Dynavax's(NASDAQ:DVAX)CpG 1018 advanced adjuvant and aluminum hydroxide (alum).","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":51,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/863001417"}
精彩评论